CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

CRISPR Therapeutics' stock price target has been reaffirmed at $80 by Citizens, who maintain a Market Outperform rating for the company's shares. The firm highlights the company's successful commercialization of a first gene-editing based cell therapy and its pipeline of late-stage assets, particularly in cardiovascular and metabolic indications.

Recent data from 15 Phase 1a patients showed significant reductions in various lipid levels, further bolstering analyst confidence in the company's pipeline. Additionally, the FDA expanded the label for CRISPR Therapeutics' gene therapy CASGEVY to include patients as young as two years old with specific conditions, adding to the positive outlook on the company's market potential.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.